Our research is focused on identifying new drugs for the
treatment of cancer and understanding the molecular mechanism of known drugs to
improve their use. Our laboratory has
expertise natural products drug discovery.
Many of the most useful drugs used to treat cancer target microtubules.
We have discovered many new microtubule targeting agents from nature and in
collaboration with synthetic chemists.
Interrupting the functions of microtubules is detrimental to cells and
particularly to abnormal “unbalanced” cancer cells, thus leading to anticancer
effects. The identification of new
microtubule disrupting agents that can overcome drug resistance that limits the
efficacy of our current anticancer drugs is one of our goals as is
understanding how these drugs cause anticancer effects.
Rohena CC, Mooberry SL. Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities. Nat Prod Rep. 2014 Feb 11;31(3):335-55.
Du L, Robles AJ, King JB, Powell DR, Miller AN, Mooberry SL, Cichewicz RH. Crowdsourcing natural products discovery to access uncharted dimensions of fungal metabolite diversity. Angew Chem Int Ed Engl. 2014 Jan 13;53(3):804-9.
Risinger AL, Li J,
Bennett MJ, Rohena CC, Peng J, Schriemer DC, Mooberry SL. Taccalonolide binding to tubulin imparts microtubule stability and potent in vivo activity. Cancer
Res. 2013 Nov 15;73(22):6780-92.
Rohena CC, Peng J, Johnson TA, Crews P, Mooberry SL. Chemically diverse microtubule stabilizing agents initiate distinct mitotic defects and dysregulated expression of key mitotic kinases. Biochem Pharmacol. 2013 Apr 15;85(8):1104-14.
RM, Peng J, Fest GA, Dakshanamurthy S, Frantz DE, Brown ML, Mooberry SL. Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site.
Mol Pharmacol. 2012 Mar;81(3):431-9.